Inogen (NASDAQ:INGN) Given Hold Rating at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Inogen (NASDAQ:INGN) in a report issued on Wednesday,Benzinga reports.

Separately, StockNews.com upgraded shares of Inogen from a “hold” rating to a “buy” rating in a research note on Monday, February 10th.

Inogen Trading Down 14.8 %

INGN opened at $8.11 on Wednesday. The company’s 50 day moving average is $10.20 and its 200-day moving average is $10.26. Inogen has a 1-year low of $5.82 and a 1-year high of $13.33. The company has a market cap of $193.16 million, a P/E ratio of -3.60 and a beta of 1.02.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in Inogen by 2.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock valued at $8,692,000 after buying an additional 23,891 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Inogen by 0.6% in the 4th quarter. Ameriprise Financial Inc. now owns 848,980 shares of the medical technology company’s stock valued at $7,785,000 after buying an additional 5,148 shares during the last quarter. Bridgeway Capital Management LLC raised its holdings in Inogen by 4.7% in the 4th quarter. Bridgeway Capital Management LLC now owns 631,230 shares of the medical technology company’s stock valued at $5,788,000 after buying an additional 28,517 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Inogen by 25.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after buying an additional 123,208 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Inogen by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock worth $5,377,000 after purchasing an additional 5,921 shares during the last quarter. Institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.